Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Gallium Maltolate in Recurrent Glioblastoma: NCT07515924 Clinical Landscape Report 2026
16 September 2026
NCT07515924 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Umbilical cord mesenchymal stem cell-derived extracellular vesicles(Vinmec Research Institute of Stem Cell and Gene Technology) in Idiopathic Pulmonary Fibrosis: NCT07515066 Clinical Landscape Report 2026
16 September 2026
NCT07515066 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab Biosimilar (Shanghai Henlius Biotech) in Muscle Invasive Bladder Urothelial Carcinoma: NCT07518043 Clinical Landscape Report 2026
16 September 2026
NCT07518043 clinical landscape for Muscle Invasive Bladder Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Aminolevulinic Acid Hydrochloride in Glioblastoma, IDH-Wildtype: ISRCTN14636207 Clinical Landscape Report 2026
16 September 2026
ISRCTN14636207 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
REC-4539 in Ovarian Cancer: NCT07517198 Clinical Landscape Report 2026
16 September 2026
NCT07517198 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GV-907 in Glioblastoma, IDH-Wildtype: NCT07520214 Clinical Landscape Report 2026
16 September 2026
NCT07520214 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MTS-109 in Idiopathic Inflammatory Myopathies: NCT07526350 Clinical Landscape Report 2026
16 September 2026
NCT07526350 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
CN-201 in Follicular Lymphoma: NCT07519772 Clinical Landscape Report 2026
16 September 2026
NCT07519772 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Metformin Hydrochloride in Idiopathic Pulmonary Fibrosis: NCT07520110 Clinical Landscape Report 2026
16 September 2026
NCT07520110 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PF-08046033 (GPS) in Esophageal Carcinoma: NCT07519655 Clinical Landscape Report 2026
16 September 2026
NCT07519655 clinical landscape for Esophageal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Idiopathic Inflammatory Myopathies: NCT07526493 Clinical Landscape Report 2026
16 September 2026
NCT07526493 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Pegfilgrastim (Amgen) in Triple Negative Breast Cancer: NCT07525869 Clinical Landscape Report 2026
16 September 2026
NCT07525869 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.